Vascular Endothelial Growth Factor Inhibits Bone Morphogenetic Protein 2 Expression in Rat Mesenchymal Stem Cells

Overview

Journal Tissue Eng Part A

Specialties Anatomy & Histology
Biomedical Engineering
Biotechnology

Date 2009 Sep 17

PMID 19754224

Citations 17

Authors

Bjorn H Schonmeyr

Marc Soares

Tomer Avraham

Nicholas W Clavin

Fredrik Gewalli

Babak J Mehrara

Affiliations

Soon will be listed here.

Abstract

Introduction: While several studies report that bone morphogenetic proteins (BMPs) and vascular endothelial growth factor (VEGF) can act synergistically to improve bone tissue engineering, others suggest that VEGF inhibits osteogenesis. The purpose of these experiments was therefore to evaluate the effect of dual transfection of these growth factors and potential mechanisms of interaction on gene expression and osteogenesis in vitro and in vivo.

Methods: Marrow-derived mesenchymal stem cells (MSCs) were exposed to recombinant VEGF protein or transfected with adenoviruses encoding BMP2, VEGF, or LacZ in a variety of ratios. Alterations in gene and protein expression in vitro as well as bone formation in vivo were assessed.

Results: MSC exposure to AdV-VEGF or recombinant VEGF inhibited BMP2 mRNA expression, protein production, and MSC differentiation. Coculture experiments revealed that BMP2 suppression occurs through both an autocrine and a paracrine mechanism, occurring at the transcriptional level. Compared to controls, cotransfection of VEGF and BMP2 transgenes prevented ectopic bone formation in vivo.

Conclusion: VEGF is a potent inhibitor of BMP2 expression in MSCs, and supplementation or overexpression of VEGF inhibits osteogenesis in vitro and ectopic bone formation in vivo. Strategies to utilize MSCs in bone tissue engineering therefore require careful optimization and precise delivery of growth factors for maximal bone formation.

Citing Articles

Resorbable Mg-Containing Phosphates for Bone Tissue Repair.

Kazakova G, Safronova T, Golubchikov D, Shevtsova O, Rau J Materials (Basel). 2021; 14(17).

PMID: 34500951 PMC: 8432688. DOI: 10.3390/ma14174857.

Coculture of Endothelial and Stromal Cells to Promote Concurrent Osteogenesis and Vasculogenesis.

Schott N, Stegemann J Tissue Eng Part A. 2021; 27(21-22):1376-1386.

PMID: 33599160 PMC: 8827126. DOI: 10.1089/ten.TEA.2020.0330.

Challenges in Bone Tissue Regeneration: Stem Cell Therapy, Biofunctionality and Antimicrobial Properties of Novel Materials and Its Evolution.

Riester O, Borgolte M, Csuk R, Deigner H Int J Mol Sci. 2020; 22(1).

PMID: 33375478 PMC: 7794985. DOI: 10.3390/ijms22010192.

Coupling Osteogenesis and Vasculogenesis in Engineered Orthopedic Tissues.

Schott N, Friend N, Stegemann J Tissue Eng Part B Rev. 2020; 27(3):199-214.

PMID: 32854589 PMC: 8349721. DOI: 10.1089/ten.TEB.2020.0132.

Adenoviral mediated mono delivery of BMP2 is superior to the combined delivery of BMP2 and VEGFA in bone regeneration in a critical-sized rat calvarial bone defect.

Sharma S, Xue Y, Xing Z, Yassin M, Sun Y, Lorens J Bone Rep. 2019; 10:100205.

PMID: 31193299 PMC: 6525280. DOI: 10.1016/j.bonr.2019.100205.

References

Peterson B, Zhang J, Iglesias R, Kabo M, Hedrick M, Benhaim P . Healing of critically sized femoral defects, using genetically modified mesenchymal stem cells from human adipose tissue. Tissue Eng. 2005; 11(1-2):120-9. DOI: 10.1089/ten.2005.11.120. View

Minamide A, Tamaki T, Kawakami M, Hashizume H, Yoshida M, Sakata R . Experimental spinal fusion using sintered bovine bone coated with type I collagen and recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976). 1999; 24(18):1863-70; discussion 1871-2. DOI: 10.1097/00007632-199909150-00002. View

Nilsson O, Urist M, Dawson E, Schmalzried T, Finerman G . Bone repair induced by bone morphogenetic protein in ulnar defects in dogs. J Bone Joint Surg Br. 1986; 68(4):635-42. DOI: 10.1302/0301-620X.68B4.3733844. View

Wu B, Zheng Q, Guo X, Wu Y, Wang Y, Cui F . Preparation and ectopic osteogenesis in vivo of scaffold based on mineralized recombinant human-like collagen loaded with synthetic BMP-2-derived peptide. Biomed Mater. 2008; 3(4):044111. DOI: 10.1088/1748-6041/3/4/044111. View

Hoerstrup S, Kadner A, Melnitchouk S, Trojan A, Eid K, Tracy J . Tissue engineering of functional trileaflet heart valves from human marrow stromal cells. Circulation. 2002; 106(12 Suppl 1):I143-50. View

Pittenger M, Mackay A, Beck S, Jaiswal R, Douglas R, Mosca J . Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284(5411):143-7. DOI: 10.1126/science.284.5411.143. View

Yang D, Guo T, Nie C, Morris S . Tissue-engineered blood vessel graft produced by self-derived cells and allogenic acellular matrix: a functional performance and histologic study. Ann Plast Surg. 2009; 62(3):297-303. DOI: 10.1097/SAP.0b013e318197eb19. View

Geiger F, Lorenz H, Xu W, Szalay K, Kasten P, Claes L . VEGF producing bone marrow stromal cells (BMSC) enhance vascularization and resorption of a natural coral bone substitute. Bone. 2007; 41(4):516-22. DOI: 10.1016/j.bone.2007.06.018. View

Hayami T, Funaki H, Yaoeda K, Mitui K, Yamagiwa H, Tokunaga K . Expression of the cartilage derived anti-angiogenic factor chondromodulin-I decreases in the early stage of experimental osteoarthritis. J Rheumatol. 2003; 30(10):2207-17. View

10.

Lohela M, Bry M, Tammela T, Alitalo K . VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009; 21(2):154-65. DOI: 10.1016/j.ceb.2008.12.012. View

11.

Maes C, Carmeliet P, Moermans K, Stockmans I, Smets N, Collen D . Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev. 2002; 111(1-2):61-73. DOI: 10.1016/s0925-4773(01)00601-3. View

12.

Peng H, Wright V, Usas A, Gearhart B, Shen H, Cummins J . Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest. 2002; 110(6):751-9. PMC: 151123. DOI: 10.1172/JCI15153. View

13.

Baker B, Mauck R . The effect of nanofiber alignment on the maturation of engineered meniscus constructs. Biomaterials. 2007; 28(11):1967-77. PMC: 1847368. DOI: 10.1016/j.biomaterials.2007.01.004. View

14.

Gerber H, Vu T, Ryan A, Kowalski J, Werb Z, Ferrara N . VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 1999; 5(6):623-8. DOI: 10.1038/9467. View

15.

Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M . Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004; 22(3):377-84. DOI: 10.1634/stemcells.22-3-377. View

16.

Lee D, Park B, Lee M, Lee J, Kim J, Yang H . Chemotactic migration of human mesenchymal stem cells and MC3T3-E1 osteoblast-like cells induced by COS-7 cell line expressing rhBMP-7. Tissue Eng. 2006; 12(6):1577-86. DOI: 10.1089/ten.2006.12.1577. View

17.

Li G, Corsi-Payne K, Zheng B, Usas A, Peng H, Huard J . The dose of growth factors influences the synergistic effect of vascular endothelial growth factor on bone morphogenetic protein 4-induced ectopic bone formation. Tissue Eng Part A. 2009; 15(8):2123-33. PMC: 2811054. DOI: 10.1089/ten.tea.2008.0214. View

18.

Okuyama H, Krishnamachary B, Zhou Y, Nagasawa H, Bosch-Marce M, Semenza G . Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor 1. J Biol Chem. 2006; 281(22):15554-63. DOI: 10.1074/jbc.M602003200. View

19.

Senger D, Connolly D, Van de Water L, Feder J, Dvorak H . Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990; 50(6):1774-8. View

20.

Alhadlaq A, Mao J . Tissue-engineered osteochondral constructs in the shape of an articular condyle. J Bone Joint Surg Am. 2005; 87(5):936-44. DOI: 10.2106/JBJS.D.02104. View